Literature DB >> 376062

Group B streptococcal infection: a review and update.

J M Knox.   

Abstract

The problems posed by the sudden increase in serious group B streptococcal disease among infants since the early 1970s are described and discussed. Virtually all offspring of colonised mothers harbour the organism and infection develops in about 1% of these infants. The mortality rate, even with immediate antibiotic treatment of early onset disease, is 30%; delay in treatment leads to much higher mortality. Late onset disease starting around the seventh to ninth day of life, but sometimes as late as the second month, is less frequently fatal. Preventive measures include active and passive immunisation or intravenous ampicillin during labour. Experimental evidence indicates that each of these methods gives protection.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376062      PMCID: PMC1045604          DOI: 10.1136/sti.55.2.118

Source DB:  PubMed          Journal:  Br J Vener Dis        ISSN: 0007-134X


  13 in total

1.  Carrier rate of group B streptococci with relevance to neonatal infections.

Authors:  L Bevanger
Journal:  Infection       Date:  1974       Impact factor: 3.553

2.  Group B streptococcal neonatal and infant infections.

Authors:  R A Franciosi; J D Knostman; R A Zimmerman
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

3.  Transmission of group B streptococci among parturient women and their neonates.

Authors:  C J Baker; F F Barrett
Journal:  J Pediatr       Date:  1973-12       Impact factor: 4.406

4.  Neurological sequelae of group B streptococcal neonatal infection.

Authors:  K A Horn; R A Zimmerman; J D Knostman; W T Meyer
Journal:  Pediatrics       Date:  1974-04       Impact factor: 7.124

5.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

6.  Editorial: Neonatal group B streptococcal infection.

Authors:  G H McCracken; W E Feldman
Journal:  J Pediatr       Date:  1976-08       Impact factor: 4.406

7.  Epidemiology of group-B streptococcal carriage in pregnant women and newborn infants.

Authors:  P Ferrieri; P P Cleary; A E Seeds
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

8.  Colonization with group B streptococci in girls under 16 years of age.

Authors:  M R Hammerschlag; C J Baker; S Alpert; D L Kasper; I Rosner; P Thurston; B J Webb; W M McCormack
Journal:  Pediatrics       Date:  1977-10       Impact factor: 7.124

9.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  5 in total

1.  Adherence of Streptococcus agalactiae to synchronously growing human cell monolayers without lipoteichoic acid involvement.

Authors:  S Miyazaki; O Leon; C Panos
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

Review 2.  Neonatal infections: group B streptococcus.

Authors:  Paul Trafford Heath; Luke Anthony Jardine
Journal:  BMJ Clin Evid       Date:  2010-09-27

Review 3.  Neonatal infections: group B streptococcus.

Authors:  Paul T Heath; Luke Anthony Jardine
Journal:  BMJ Clin Evid       Date:  2014-02-28

Review 4.  Neonatal infections: group B streptococcus.

Authors:  James Hanley
Journal:  BMJ Clin Evid       Date:  2008-01-16

5.  Teichoic acids of Streptococcus agalactiae: chemistry, cytotoxicity, and effect on bacterial adherence to human cells in tissue culture.

Authors:  J C Goldschmidt; C Panos
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.